The use of tetrahydrofolate natural stereoisomeric forms in obtaining pharmaceutical compositions intended to influence the level of homocysteine, in particular to maintain the process demetilirovania homocysteine

 

Proposed: the use of tetrahydrofolate natural stereoisomeric form, formerly known as inhibitors of platelet aggregation, as an active ingredient for a pharmaceutical composition intended to influence homocysteine levels, including reduction of hyperhomocysteinemia in the prevention and treatment of cardiovascular disease or in the prevention of disorders of the neural tube, as well as pharmaceutical compositions on the basis of these tetrahydrofolate and vitamins B6 and/or B12. The invention expands the Arsenal of the declared destination. 5 C and 4 C.p. f-crystals.

Description text in facsimile form (see graphic part).

Claims

1. The use of tetrahydrofolate in natural stereoisomeric form, as active ingredient to obtain a pharmaceutical composition intended to influence the level of homocysteine.

2. The use of tetrahydrofolate in natural stereoisomeric form, as active ingredient to obtain a pharmaceutical composition intended for the reduction of hyperhomocysteinemia in the prevention and treatment serve active ingredient for a pharmaceutical composition, designed for reduction of hyperhomocysteinemia in the prevention of disorders of the neural tube.

4. The use of tetrahydrofolate in natural stereoisomeric form on PP.1-3, characterized in that as tetrahydrofolate using 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid or (6S)-tetrahydrofolic acid or their pharmaceutically acceptable salts.

5. The use of tetrahydrofolate in natural stereoisomeric form on PP.1-3, characterized in that as tetrahydrofolate using 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5-methyl-(6S)-tetrahydrofolate acid.

6. The use of tetrahydrofolate in natural stereoisomeric form on PP.1-3, characterized in that as tetrahydrofolate using 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5-methyl-(6S)-tetrahydrofolate acid and the application shall be made in case of failure of methylenetetrahydrofolate-reductase.

7. Application tetrahydrofolate-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5-methyl-(6S)-tetrahydrofolate acid and the use of exercise in the presence of thermolabile methylenetetrahydrofolate-reductase.

8. Pharmaceutical compositions intended to influence the level of homocysteine, characterized in that as the active active substance they contain in their composition in an effective amount at least one compound selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid or (6S)-tetrahydrofolic acid or their pharmaceutically acceptable salts, together with vitamins6and/or In12and auxiliary substances.

9. Pharmaceutical compositions intended to influence the level of homocysteine in the presence of thermolabile methylenetetrahydrofolate-reductase, characterized in that as the active substances they contain 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt of 5-methyl-(6S)-tetrahydrofolate acid in an effective amount together with vitamin B6and/or In12and auxiliary substances.

 

Same patents:
The invention relates to cardiology and can be used to prevent reperfusion lesions of the heart after the opening of the coronary artery in patients with acute myocardial infarction

The invention relates to organic chemistry and pharmacology, namely a mixture of isomers of the potassium salt of 2-[5(6)-nitro-1-(titanyl-3)benzimidazolyl-2-thio] acetic acid in a molar ratio of 1:3, manifesting cardiotonic activity
The invention relates to the pharmaceutical industry, namely the creation of pharmaceutical compositions with a wide range of pharmacological actions on derived orotovoy acid

The invention relates to new sulfadimethoxine benzopyranones derivative of the formula I

< / BR>
where R(5) is in one of positions 5, 6, 7 and 8, and R(1) and R(2) independently of one another denote hydrogen or alkyl with 1-6 carbon atoms, R(3) means R(10)-CnH2nR(10) means a hydrogen atom or methyl, n denotes an integer equal to 0-10, R(4) means R(13)- CrH2rand one of CH2group can be replaced by-CO-O - or-O-CO - group, R(13) denotes methyl or trifluoromethyl, r is an integer equal 0-12, R(5) means-Y-CsH2s-R(18), Y represents-O-, s indicates an integer equal to 1-8, R(18) denotes hydrogen, trifluoromethyl or phenyl, R(6) means-OR(10d) or-OCOR(10d) group, R(10d) denotes hydrogen or alkyl with 1-3 carbon atoms, denotes hydrogen or R(6) and together form a bond; and their physiologically acceptable salts

The invention relates to inhibitors tyrosinekinase type bis-indolylmaleimide compounds of the formula I

< / BR>
where Z denotes a group of General formula II

< / BR>
where A, B, X, Z, R1-R10have the meanings indicated in the claims, as well as the way they are received and drug based on these compounds
The invention relates to pharmaceutical, cosmetic and food industry
The invention relates to the field of pharmaceutical industry and relates to a method of obtaining a suppository "Epiproct", featured in complex therapy of inflammatory processes of the rectum, prostatitis, hemorrhoids, treatment for anal fissures

The invention relates to medicine

The invention relates to novel condensed to thienopyrimidine formula I and their physiologically acceptable salts, having the effect of inhibitors of phosphodiesterase V(PDE V), and which can be used for the treatment of diseases of the cardiovascular system and for the treatment and/or therapy of disorders of potency

The invention relates to new compounds of the formula (I):

wherein R1is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (ISO)hyalinella, tetrahydro(ISO)hyalinella, 3,4-dihydro-1H-izokhinolinom, romaniam or camphor group, and these groups optionally can be substituted by one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxyl; R2and R3independently are H or (1-8C)alkyl; R4is (1-8C)alkyl or (3-8C)cycloalkyl; or R3and R4together with the nitrogen atom to which they are linked, are a nonaromatic (4-8)membered cycle, optionally containing another heteroatom, the cycle is optionally substituted (1-8C)alkyl or SO2is(1-8C)alkyl; Q is a spacer having a chain length from 10 to 70 atoms; and Z is a negatively charged oligosaccharide residue comprising from two to six monosaccharide units, the charge is compensated by positively charged counterions, or its pharmaceutically acceptable salts or prodrugs and pharmaceutical compositions having antimicrobial activity

The invention relates to organic chemistry and pharmacology, and relates new connection - 1-(1,1-dissociator-3)-2-morpholinobenzenediazonium hydrochloride, increasing resistance to acute hypoxia with hypercapnia

The invention relates to new indole derivative of the formula I

where two of R1a, Rlb, Rlc, Rldindependently from each other denote H, F, I, Cl, Br, (C1-C4)alkyl, phenyl, phenyl-(C1-WITH4)alkyl, (C1-C4)alkoxy, phenyl-(C1-C4)alkoxy, phenyloxy, HE, -NR5aR5b, -SOn-R6c, n is 1-2, and are the same or different, and two other mean N; where all residues R5a, R5b, R6cif present in the molecule more than once, are independent from each other and may be each the same or different; one of R2and R3means -(CH2)p-CO-R8and the other denotes H, F, Cl, Br, or -(CH2)p-CO-R8; p is 0, 1 or 2; R8means-NR9R10, -OR10; A represents the bivalent residue of(C1-C4)alkyl, which is saturated or which contains a triple bond, or -(C1-C4)alkyl-CO-NH-, where the nitrogen is associated with R4; R4means phenyl, which is substituted by one residue R15bor pyridyl, which is unsubstituted or substituted14on the nitrogen atom; all their stereozoom

The invention relates to biologically compatible carriers of oxygen for administration to patients as a Supplement or partial substitution of whole blood

The invention relates to aqueous pharmaceutical compositions of erythropoietin that are free from the products of human serum, stable amino acid, sorbitan mono-9-octadecenoate poly(oxy-1,2-ethandiyl) derived
The invention relates to the field of medicine and relates to adhesive compositions to stop bleeding on the basis of factor VIII
The invention relates to the field of pharmaceutical industry

The invention relates to new compounds of General formula I

R1-A-B-D-En-R2 (I)

in which R1 represents R12C(O), and R12 is selected from the group consisting of alkenyl, alkenylacyl or alkenylamine; And is a group A1-A2-A3, where A1 represents NH, A2 is a CHR93 in which R93 is 4-amidinophenoxy; A3 represents C(O); is a group B1-B2-B3, where B1 represents NH; B2 is a CHR97 where R97 represents ethyl, which is substituted in position 2 by hydroxycarbonyl or allyloxycarbonyl; B3 represents C(O); D represents a group D1-D2-D3, where D1 represents NH, D2 represents CR81R82 where R81 and R82 are independently selected from the group consisting of hydrogen and unsubstituted or substituted residues of alkyl, aryl, arylalkyl, heteroallyl; D3 represents C(O); Enis a (E1-E2-E3)nin which n is 0 or 1; E1 represents NR70, where R70 is H; E2 represents CR71R72, where R71 and R72 include independently selected from the group consisting of hydrogen and unsubstituted or substituted residues of alkyl, aryl, arylalkyl, heteroallyl; E3 represents C(O); R2 is a NR21R22 where R21 of iillil and geterotsiklicheskikh, moreover, the alkyl contains from 1 to 13 carbon atoms, alkenyl contains from 2 to 13 carbon atoms, aryl and heteroaryl contain from 5 to 13 ring carbon atoms, where in the rest of heteroaryl one or more carbon atoms are replaced by heteroatoms selected from the group consisting of N, O and S; heteroseksualci contains from 3 to 8 ring carbon atoms, of which from one to three carbon atoms are replaced by heteroatoms selected from the group consisting of N, O and S; in any stereoisomeric forms or their mixtures in any ratio, and their pharmaceutically acceptable salts; the method of obtaining compounds of General formula I, including linking protected amino acids; to pharmaceutical compositions which are able to exert an antithrombotic effect by activated factor VII(FVIIa) blood coagulation

The invention relates to medicine

The invention relates to medicine, in particular to the cholinergic antagonist pontefino (hydrochloride of 1-phenyl-1-cyclopentyl-4-piperidino-2-buten-1-ol, (I) exhibiting a pronounced selectivity in relation to muscarinic receptors belong to a subtype of M4
Up!